`a`
Mathematical Biosciences and Engineering (MBE)
 

The role of the cytokines IL-27 and IL-35 in cancer
Pages: 1203 - 1217, Issue 6, December 2015

doi:10.3934/mbe.2015.12.1203      Abstract        References        Full text (1021.9K)           Related Articles

Avner Friedman - Mathematical Biosciences Institute, The Ohio State University, Columbus, OH 43210, United States (email)
Kang-Ling Liao - Mathematical Biosciences Institute, The Ohio State University, Columbus, OH, United States (email)

1 K. Asadullah, W. Sterry and H. D. Volk, Interleukin-10 Therapy - Review of a New Approach, Pharmacological Reviews, 55 (2003), 241-269.
2 K. C. Boelte, L. E. Gordy, S. Joyce, M. A. Thompson, L. Yang and P. C. Lin, Rgs2 mediates pro-angiogenic function of myeloid derived suppressor cells in the tumor microenvironment via upregulation of MCP-1, PLoS ONE, 6 (2011), e18534.
3 F. Broere, S. G. Apasov, M. V. Sitkovsky and W. V. Eden, T cell subsets and T cell-mediated immunity, Principles of Immunopharmacology: 3rd revised and extended edition, 2011.
4 M. J. Brunda, L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard, M. Murphy, S. F. Wolf and M. K. Gately, Antitumor and antimetastatic activity of interleukin 12 against murine tumors, The Journal of Experimental Medicine, 178 (1993), 1223-1230.
5 B. D. Car, V. M. Eng, J. M. Lipman and T. D. Anderson, The toxicology of interleukin-12: A review, Toxicologic Pathology, 27 (1999), 58-63.
6 V. Chaturvedi, L. W. Collison, C. S. Guy, C. J. Workman and D. A. A. Vignali, Human regulatory T cells eequire Interleukin-35 to mediate suppression and infectious tolerance, J. Immunol., 186 (2011), 6661-6666.
7 F. Cavallo, P. Signorelli, M. Giovarelli, P. Musiani, A. Modesti, M. J. Brunda, M. P. Colombo and G. Forni, Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (il-12) or other cytokines compared with exogenous il-12, Journal of the National Cancer Institute, 89 (1997), 1049-1058.
8 D. Chen, J. M. Roda, C. B. Marsh, T. D. Eubank and A. Friedman, Hypoxia inducible factors-mediated inhibition of cancer by GM-CSF: A mathematical model, Bull. Math. Biol., 74 (2012), 2752-2777.       
9 M. Chiyo, O. Shimozato, T. Lizasa, T. Fujisawa and M. Tagawa, Antitumor effects produced by transduction of dendritic cells-derived heterodimeric cytokine genes in murine colon carcinoma cells, Anticancer Res., 24 (2004), 3763-3767.
10 C. Cocco, S. Canale, C. Frasson, E. Di Carlo, E. Ognio, D. Ribatti, I. Prigione, G. Basso and I. Airoldi, Interleukin-23 acts as antitumor agent on childhood B-acute lymphoblastic leukemia cells, Blood, 116 (2010), 3887-3898.
11 L. W. Collison, C. J. Workman, T. T. Kuo, K. Boyd, Y. Wang, K. M. Vignali, R. Cross, D. Sehy, R. S. Blumberg and D. A. Vignali, The inhibitory cytokine IL-35 contributes to regulatory T-cell function, Nature, 450 (2007), 566-569.
12 L. W. Collison and D. A. A. Vignali, Interleukin-35: Odd one out or part of the family?, Immunol. Rev., 226 (2008), 248-262.
13 L. W. Collison, G. M. Delgoffe, C. S. Guy, K. M. Vignali, V. Chaturvedi, D. Fairweather, A. R. Satoskar, K. C. Garcia, C. A. Hunter, C. G. Drake, P. J. Murray and D. A. A. Vignali, The composition and signaling of the IL-35 receptor are unconventional, Nature immunology, 13 (2012), 290-299.
14 M. P. Colombo and G. Trinchieri, Interleukin-12 in anti-tumor immunity and immunotherapy, Cytokine Growth Factor Rev., 13 (2002), 155-168.
15 K. Eller, D. Wolf, J. M. Huber, M. Metz, G. Mayer, A. N. J. McKenzie, M. Maurer, A. R. Rosenkranz and A. M. Wolf, IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-onduced immune suppression. J. Immunology, 186 (2011), 83-91.
16 T. Eubank, R. D. Roberts, M. Galoway, Y. Wang, D. Cohn and C. Marsh, GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice, Immunity, 21 (2004), 831-842.
17 T. Eubank, R. D. Roberts, M. Khan, J. Curry, G. J. Nuovo, P. Kuppusamyl and C. Marsh, Granulocyte macrophage Colony-Stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages, Cancer Res., 69 (2009), 2133-2140.
18 T. Eubank, J. M. Roda, H. Liu, T. O'Neil and C. Marsh, Opposing roles for HIF-1$\alpha$ and HIF-2$\alpha$ in the regulation of angiogenesis by mononuclear phagocytes, Blood, 117 (2011), 323-331.
19 S. Fujii, K. Shimizu, T. Shimizu and M. T. Lotze, Interleukin-10 promotes the maintenance of antitumor CD8(+) T-cell effector function in situ, Blood, 98 (2001), 2143-2151.
20 D. I. Gabrilovich, S. O. Rosenberg and V. Bronte, Coordinated regulation of myeloid cells by tumors, Nat. Rev. Immunol., 12 (2012), 253-268.
21 H. Groux, M. Bigler, J. E. Vries and M. G. Roncarolo, Inhibitory and Stimulatory Effects of IL-10 on Human CD8$^+$ T Cells, J Immunol, 160 (1998), 3188-3193.
22 H. Grous, F. Coottrez, M. Rouleau, S. Mauze, S. Antonenko, S. Hurst, T. McNeil, M. Bigler, M. G. Roncarolo and R. L. Coffman, A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells, J. Immunol, 162 (1999), 1723-1729.
23 M. Hisada, S. Kamiya, K. Fujita, M. L. Belladonna, T. Aoki, Y. Koyanagi, J. Mizuguchi and T. Yoshimoto, Potent antitumor activity of interleukin-27, Cancer Res, 64 (2004), 1152-1156.
24 M. Y. Ho, S. J. Leu, G. H. Sun, M. H. Tao, S. J. Tang and K. H. Sun, IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities, J. Immunol., 183 (2009), 6217-6226.
25 C. A. Hunter, New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions, Nat Rev Immunol, 5 (2005), 521-531.
26 E. Itakura, R. R. Huang, D. R. Wen, E. Paul, P. Wünsch and A. J. Cochran, IL-10 expression by primary tumor cells correlates with melanoma progression from radial to vertical growth phase and development of metastatic competence, Modern Pathology, 24 (2011), 801-809.
27 T. Kaiga, M. Sato, H. Kaneda, Y. Iwakura, T. Takayama and H. Tahara, Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12, J Immunol., 178 (2007), 7571-7580.
28 K. W. Kross, J. H. Heimdal, C. Olsnes, J. Olofson and H. J. Aarstad, Tumour-associated macrophages secrete IL-6 and MCP-1 in head and neck squamous cell carcinoma tissue, Acta Otolaryngol, 127 (2007), 532-539.
29 H. H. Lee, S. S. Yang, M. T. Vo, W. J. Cho, B. J. Lee, S. H. Leem, S. H. Lee, H. J. Cha and J. W. Park, Tristetraprolin down-regulates IL-23 expression in colon cancer cells, Mol. Cells, 36 (2013), 571-576.
30 J. Li, L. Zhang, J. Zhang, Y. Wei, K. Li, L. Huang, S. Zhang, B. Gao, X. Wang and P. Lin, Interleukin 23 regulates proliferation of lung cancer cells in a concentration-dependent way in association with the interleukin-23 receptor, Carcinogenesis, 34 (2012), 658-666.
31 K.-L. Liao, X.-F. Bai and A. Friedman, Mathematical modeling of Interleukin-27 induction of anti-tumor T cells response, PLoS ONE, 9 (2014), e91844.
32 K.-L. Liao, X.-F. Bai and A. Friedman, Mathematical modeling of Interleukin 35 promoting tumor growth and angiogenesis, PLoS ONE, 9 (2014), e110126.
33 Z. Liu, J.-Q. Liu, F. Talebian, L.-C. Wu, S. Li and X.-F. Bai, IL-27 enhances the survival of tumor antigen-specific CD8$^+$ T cells and programs them into IL-10-producing, memory precursor-like effector cells, European J. of Immunology, 43 (2013), 468-479.
34 U. K. Liyanage, T. T. Moore, H. G. Joo, Y. Tanaka, V. Herrmann, G. Doherty, J. A. Drebin, S. M. Strasberg, T. J. Eberlein, P. S. Goedegebuure and D. C. Linehan, Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma, J. Immunol., 169 (2002), 2756-2761.
35 J. Long, X. Zhang, M. Wena, Q. Kong, Z. Lv, Y. An and X.-Q. Wei, IL-35 over-expression increases apoptosis sensitivity and suppresses cell growth in human cancer cells, Biochemical and Biophysical Research Communications, 430 (2013), 364-369.
36 K. Loser and S. Beissert, Regulatory T Cells: Banned Cells for Decades, J. Investigative Dermatology, 132 (2012), 864-871.
37 Y. Louzoun, C. Xue, G. B. Lesinski and A. Friedman, A mathematical model for pancreatic cancer growth and treatments, J. Theor. Biol., 351 (2014), 74-82.       
38 T. A. Mace, Z. Ameen, A. Collins, S. E. Wojcik, M. Mair, G. S. Young, J. R. Fuchs, T. D. Eubank, W. L. Frankel, T. Bekaii-Saab, M. Bloomston and G. B. Lesinski, Pancreatic cancer associated stellate cells promote differentiation of myeloid-derived suppressor cells in a stat3-dependent manner, Cancer Res., 73 (2013), 3007-3018.
39 E. Marshall, Cancer trial of interleukin-12 halted, Science (Wash DC), 268 (1995), p1555.
40 N. Morishima, I. Mizoguchi, M. Okumura, Y. Chiba, M. Shimizu, M. Xu, M. Matsui, J. Mizuguchi and T. Yoshimoto, A prvotal role for interleukin-27 in CD8$^+$ T cell functions and generation of cutotoxic T lymphocytes, J. Biomed Biotechnol, 2010 (2010), Article ID 605483, 10 pages.
41 J. B. Mumm, J. Emmerich, X. Zhang, I. Chan, L. Mauze, S. Wu, S. Blaisdell, B. Basham, J. Dai, J. Grein, C. Sheppard, K. Hong, C. Cutler, S. Turner, D. Laface, M. Kleinscher, M. Judo, G. Ayanoglu, J. Langowski, D. Paporello, B. Gu, E. Murphy, V. Sriram, S. Naravula, B. Desai, S. Medicherla, W. Seghezzi, T. McClanahan, S. Csnnon-Carlson, A. M. Beebe and M. Oft, IL-10 elicits IFN-$\gamma$-dependent tumor immune surveillance, Cancer Cell, 20 (2011), 781-796.
42 M. B. Omary, A. Lugea, A. W. Lowe and S. J. Pandol, The pancreatic stellate cell: a star on the rise in pancreatic diseases, J. Clin Invest., 117 (2007), 50-59.
43 J. G. Quatromoni, E. Suzuki, O. Okusanya, B. F. Judy, P. Bhojnagarwala, O. Venegas, E. Eruslanov, J. D. Predina, S. M. Albelda and S. Singhal, The timing of TGF-$\beta$ inhibition affects the generation of antigen-specific CD8$^+$ T cells, BMC Immunol, 14 (2013), p30.
44 A. L. Rakhmilevich, K. Janssen, J. Turner, J. Culp and N. S. Yang, Cytokine gene therapy of cancer using gene gun technology: Superior antitumor activity of interleukin-12, Hum Gene Ther, 8 (1997), 1303-1311.
45 J. C. Reay, Therapeutic gene therapy for cancer with interleukin-23, 2010.
46 S. Sakaguchi, K. Wing, Y. Onishi, P. Prieto-Martin and T. Yamaguchi, Regulatory T cells: how do they suppress immune responses?, International Immunology, 21 (2012), 1105-1111.
47 R. Salcedo, J. A. Hixon, J. K. Stauffer, R. Jalah, A. D. Brooks, T. Khan, R. M. Dai, L. Scheetz, E. Lincoln, T. C. Back, D. Powell, A. A. Hurwitz, T. J. Sayers, R. Kastelein, G. N. Pavlakis, B. K. Felber, G. Trinchieri and J. M. Wigginton, Immunologic and therapeutic synergy of IL-27 and IL-2: Ehancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow, J. Immunol., 182 (2009), 4328-4338.
48 R. Salcedo, J. K. Stauffer, E. Lincoln, T. C. Back, J. A. Hixon, C. Hahn, K. Shafer-Weaver, A. Malyguine, R. Kastelein and J. M. Wigginton, IL-27 mediated complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8$^+$ T cells, J. Immunol., 173 (2004), 7170-7182.
49 F. W. Shek, R. C. Benyon, F. M. Walker, P. R. McCrudden, S. L. Pender, E. J. Williams, P. A. Johnson, C. D. Johnson, A. C. Bateman, D. R. Fine and J. P. Iredale, Expression of transforming growth factor-beta 1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis, Am. J. Pathol., 160 (2002), 1787-1798.
50 Y. Shinozaki, S. Wang, Y. Miyazaki, K. Miyazaki, H. Yamada, Y. Yoshikai, H. Hara and H. Yoshida, Tumor-specific cutotoxic T cell generation and dendritic cell function are differentially regulated by interleukin 27 during development of anti-tumor immunity, Int. J. Cancer, 124 (2009), 1372-1378.
51 L. Strauss, C. Bergmann, M. Szczepanski, W. Gooding, J. T. Johnson and T. L. Whiteside, A Unique subset of CD4$^+$$CD25^{high}$Fox $p3^{+}$ T cells secreting Interleukin-10 and transforming growth factor-$\beta 1$ mediates suppression in the tumor microenvironment, Clinical Cancer Research, 13 (2007), 4345-4354.
52 A. Swarbrick, S. R. Junankar and M. Batten, Could the properties of IL-27 make it an ideal adjuvant for anticancer immunotherapy?, Oncoimmunology, 2 (2013), e25409.
53 B. Szomolay, T. Eubank, R. Roberts, C. Marsh and A. Friedman, Modeling the inhibition of breast cancer growth by GM-CSF, J. Theor. Biol., 303 (2012), 141-151.       
54 T. Tanikawa, C. M. Wilke, I. Kryczek, G. Y. Chen, J. Kao, G. Nú$\ddotn$ez and W. Zou, Interleukin-10 anlation promotes tumor developments, growth, and metastasis, Cancer Res., 72 (2012), 420-429.
55 M. W. Teng, M. D. Vesely, H. Duret, N. McLaughlin, J. E. Towne, R. D. Schreiber and M. J. Smyth, Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state, Cancer Res., 72 (2012), 3987-3996.
56 D. A. Thomas and J. Massagué, TGF-$\beta$ directly targets cytotoxic T cell functions during tumor evasion of immune surveillance, Cancer Cell, 8 (2005), 369-380.
57 M. M. Tiemessen, S. Kunzmann, C. B. Schmidt-Weber, J. Garssen, C. A. Bruijnzeel-Koomen, E. F. Knol and E. van Hoffen, Transforming growth factor-beta inhibits human antigen-specific CD4$^+$ T cell proliferation without modulating the cytokine response, Int Immunol, 14 (2003), 1495-1504.
58 D. A. A. Vignali, L. W. Collison and C. J. Workman, How regulatory T cells work, Nat. Rev. Immunol., 8 (2008), 523-532.
59 D. A. A. Vignali and V. K. Kuchroo, IL-12 family cytokines: Immunological playmakers, Nature immunology, 13 (2012), 722-728.
60 R. Wang, M. Lu, J. Zhang, S. Chen, X. Luo, Y. Qin and H. Chen, Increased IL-10 mRNA expression in tumor-associated macrophage correlated with late stage of lung cancer, J. Experimental and Clinical Cancer Research, 30 (2011), p62.
61 V. Wang, J. Q. Liu, Z. Liu, R. Shen, G. Zhang, J. Xu, Y. Fend and X. F. Bai, Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis, J. Immuno., (2013).
62 E. D. Wojno, N. Hosken, J. S. Stumhofer, A. C. O'Hara, E. Mauldin, Q. Fang, L. A. Turka, S. D. Levin and C. A. Hunter, A role for IL-27 in limiting T regulatory cell populations, J Immunol, 187 (2011), 266-273.
63 D. Wolf, A. M. Wolf, H. Rumpold, H. Fiegl, A. G. Zeimet, E. Muller-Holzner, M. Deibl, G. Gastl, E. Gunsilius and C. Marth, The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer, Clin. Cancer Res., 11 (2005), 8326-8331.
64 M. Xu, I. Mizoguchi, N. Morishima, Y. Chiba, J. Mizuguchi and T. Yoshimoto, Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27, Clinical and Developmental immunology, 2010 (2010), Article ID 832454, 9 pages.
65 W. C. Yang, G. Ma, S. H. Chen and P. Y. Pan, Polarization and reprogramming of myeloid-derived suppressor cells, J. Mol Cell Biol., 5 (2013), 207-209.
66 N. G. Yousif, S. Alhasani, H. Slimani, J. Doug, B. I. Mohammad, S. Machil, A. A. Deb and N. Romalid, The role of IL-23 in regulating metastatic prostate cancer through STAT-3/ROR-gamma signaling, 2014 Genitourinary Cancer Symposium, 2014.
67 J.-C. Zeng, Z. Zhang, T.-Y. Li, Y.-F. Liang, H.-M. Wang, J.-J. Bao, J.-A. Zhang, W.-D. Wang, W.-Y. Xiang, B. Kong, Z.-Y. Wang, B.-H. Wu, X.-D. Chen, L. He, S. Zhang, C.-Y. Wang and J.-F. Xu, Assessing the role of IL-35 in colorectal cancer progression and prognosis, Int J Clin Exp Pathol, 6 (2013), 1806-1816.
68 S. Zhu, D. A. Lee and S. Li, IL-12 and IL-27 sequential gene therapy via intramuscular eletroporation delivery for eliminating distal aggressive tumors, J. Immunol., 184 (2010), 2348-2354.
69 O. Zolochevska, A. O. Diaz-Qui$\ddotn$ones, J. Ellis and M. L. Figueiredo, Interleukin-27 expression modifies prostate cancer cell crosstalk with bone and immune cells in vitro, J. Cell Physiol., 228 (2013), 1127-1136.

Go to top